Showing results (1-10 of 26) with videos related to

Sort By:
Pageof 3
Nature|June 13, 2003
Contemporaneous formation of chondrules and refractory inclusions in the early Solar SystemShoichi Itoh, Hisayoshi Yurimoto
Gan to Kagaku Ryoho. Cancer & Chemotherapy|August 4, 2026
[Development of Therapies Targeting Non-G12C KRAS Mutations (Focusing on G12D and Pan-RAS)]Shoichi Itoh, Miyako Satouchi
Journal of Periodontology|October 31, 2020
Impact of adjunctive procedures on recombinant human fibroblast growth factor-2-mediated periodontal regeneration therapy: A retrospective studyYohei Nakayama, Hideo Matsuda, Shoichi Itoh, et al.
Journal of Magnetic Resonance (San Diego, Calif. : 1997)|December 31, 2017
Mechanically detected terahertz electron spin resonance using SOI-based thin piezoresistive microcantileversEiji Ohmichi, Toshihiro Miki, Hidekazu Horie, et al.
Science (New York, N.Y.)|June 16, 2007
Remnants of the early solar system water enriched in heavy oxygen isotopesNaoya Sakamoto, Yusuke Seto, Shoichi Itoh, et al.
Respiratory Investigation|March 1, 2020
The efficacy of carboplatin plus nanoparticle albumin-bound paclitaxel after cisplatin plus pemetrexed in non-squamous non-small-cell lung cancer patientsMiho Tanaka, Yoshihiro Hattori, Tatsuya Ishii, et al.
Philosophical Transactions. Series A, Mathematical, Physical, and Engineering Sciences|April 19, 2017
The search for and analysis of direct samples of early Solar System aqueous fluidsMichael E Zolensky, Robert J Bodnar, Hisayoshi Yurimoto, et al.
BMC Cancer|February 13, 2020
A phase I/II study of weekly nab-paclitaxel plus cisplatin in chemotherapy-naïve patients with advanced non-small-cell lung cancerYoshihiro Hattori, Yuko Kono, Shoichi Itoh, et al.
Cancer Treatment and Research Communications|February 13, 2026
Biomarker analyses to predict benefit of immune checkpoint inhibitors for EGFR-mutated non-small cell lung cancerKoichi Azuma, Mitsuo Osuga, Shoichi Itoh, et al.
Lung Cancer (Amsterdam, Netherlands)|April 16, 2024
Long-term follow-up and exploratory analysis of lenvatinib in patients with metastatic or recurrent thymic carcinoma: Results from the multicenter, phase 2 REMORA trialSeiji Niho, Jun Sato, Miyako Satouchi, et al.
Pageof 3